• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France".

作者信息

Lehmann Matthieu, Pouly Jean-Luc, Barrière Paul, Boland Lauren Amy, Bean Samuel George, Jenkins Julian

机构信息

Gedeon Richter Suisse, Chemin des Mines 2, 1202 Geneva, Switzerland.

Université de Clermont Auvergne Faculté de médecine, 28 place Henri Dunant, 63000 Clermont Ferrand, France.

出版信息

Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100331. doi: 10.1016/j.eurox.2024.100331. eCollection 2024 Sep.

DOI:10.1016/j.eurox.2024.100331
PMID:39220093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11362636/
Abstract
摘要

相似文献

1
Reply to Letter to Editor from Juan-Enrique Schwarze and colleagues - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France".对胡安 - 恩里克·施瓦泽及其同事致编辑信的回复——对“确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益”的批判性评价
Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100331. doi: 10.1016/j.eurox.2024.100331. eCollection 2024 Sep.
2
A letter to editor - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.".致编辑的一封信——对“在法国接受生育治疗的女性中，评估重组人促卵泡激素α生物类似药与重组人促卵泡激素α原研药的成本效益”的批判性评价
Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100332. doi: 10.1016/j.eurox.2024.100332. eCollection 2024 Sep.
3
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益。
Eur J Obstet Gynecol Reprod Biol X. 2024 May 3;22:100311. doi: 10.1016/j.eurox.2024.100311. eCollection 2024 Jun.
4
A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility.一项比较原研促卵泡素α与生物类似药治疗不孕症的成本效益评估。
Int J Womens Health. 2016 Dec 7;8:683-689. doi: 10.2147/IJWH.S118687. eCollection 2016.
5
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.德国促卵泡素α原研药与生物类似药用于辅助生殖的成本效益评估。
Int J Womens Health. 2019 May 13;11:319-331. doi: 10.2147/IJWH.S193048. eCollection 2019.
6
Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.西班牙原创重组人促卵泡素α与重组人生长激素促卵泡素α生物类似药的比较：与新鲜胚胎移植相关的辅助生殖技术的成本效益分析
Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):203-216. doi: 10.1016/j.bpobgyn.2022.01.011. Epub 2022 Feb 8.
7
Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.在真实世界临床实践中接受原研促卵泡素α和促卵泡素α生物类似药治疗的患者的临床结局：一项回顾性研究
J Hum Reprod Sci. 2023 Apr-Jun;16(2):148-155. doi: 10.4103/jhrs.jhrs_37_23. Epub 2023 Jun 30.
8
A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.一项成本效益模型评估，比较了一种生物类似物重组人促卵泡素α制剂与其参比产品在德国、意大利和西班牙实现活产结局的情况。
J Med Econ. 2018 Nov;21(11):1096-1101. doi: 10.1080/13696998.2018.1511567. Epub 2018 Aug 31.
9
A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.一项支持 PROsPeR 评分分类的大型观察性数据研究，该分类依据活产结局对卵巢低反应患者进行分类。
Hum Reprod. 2021 May 17;36(6):1600-1610. doi: 10.1093/humrep/deab050.
10
Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.生物类似重组促卵泡素阿尔法制剂与参照产品（果纳芬®）在接受辅助生殖技术治疗的夫妇中的比较：系统评价和荟萃分析。
Reprod Biol Endocrinol. 2021 Apr 2;19(1):51. doi: 10.1186/s12958-021-00727-y.

本文引用的文献

1
Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640).对S. 黑山、C. 赫尔维格、J.-E. 施瓦泽、C. 卡斯特洛 - 布里杜、S. 马克、M. 利斯皮等人发表于《妇科与产科及人类生殖》（2023年；52(8):102640）的《法国ART的真实世界研究（REOLA）：根据重组促卵泡素起始剂量比较生物类似物重组促卵泡素与原研药》一文致编辑信的回复
J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102644. doi: 10.1016/j.jogoh.2023.102644. Epub 2023 Aug 11.
2
Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS).法国辅助生殖技术（ART）中促性腺激素用于卵巢刺激的疗效比较：来自法国全国索赔数据库（SNDS）的真实世界观察性研究。
Best Pract Res Clin Obstet Gynaecol. 2023 Jun;88:102308. doi: 10.1016/j.bpobgyn.2022.102308. Epub 2022 Dec 28.
3
A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.一项在法国开展的关于辅助生殖技术（ART）的真实世界研究（REOLA），根据重组促卵泡激素（rFSH）起始剂量，将一种生物类似药rFSH与原研药进行比较。
J Gynecol Obstet Hum Reprod. 2023 Jan;52(1):102510. doi: 10.1016/j.jogoh.2022.102510. Epub 2022 Nov 17.
4
Wastage of gonadotropins during IVF cycles: Real life data from two Italian infertility centers.体外受精周期中促性腺激素的浪费：来自两个意大利不孕不育中心的真实数据。
Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:56-60. doi: 10.1016/j.ejogrb.2021.10.013. Epub 2021 Oct 20.
5
Qualitative risk assessment of follicle stimulating hormone injectable products.卵泡刺激素注射剂产品的定性风险评估。
Expert Opin Drug Deliv. 2020 Nov;17(11):1647-1654. doi: 10.1080/17425247.2020.1813106. Epub 2020 Oct 13.
6
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.德国促卵泡素α原研药与生物类似药用于辅助生殖的成本效益评估。
Int J Womens Health. 2019 May 13;11:319-331. doi: 10.2147/IJWH.S193048. eCollection 2019.
7
A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.从法国的角度对接受医学辅助生殖计划的患者中，将原研促卵泡素α与其生物类似药进行成本效益分析。
J Med Econ. 2018 Dec 5;22(1):108-115. doi: 10.1080/13696998.2018.1551226.
8
A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.一项成本效益模型评估，比较了一种生物类似物重组人促卵泡素α制剂与其参比产品在德国、意大利和西班牙实现活产结局的情况。
J Med Econ. 2018 Nov;21(11):1096-1101. doi: 10.1080/13696998.2018.1511567. Epub 2018 Aug 31.
9
Cost-Effectiveness Analysis of the Gonadotropin Treatments HP-hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis.法国辅助生殖技术中促性腺激素治疗 HP-hMG 和 rFSH 的成本效益分析：马尔可夫模型分析。
Appl Health Econ Health Policy. 2018 Feb;16(1):65-77. doi: 10.1007/s40258-017-0361-7.
10
Bemfola fixed dose pens potentially reduce drug wastage and associated costs of infertility treatment.倍美力预充式注射笔有可能减少药物浪费以及不孕症治疗的相关费用。
Hum Fertil (Camb). 2018 Dec;21(4):275-280. doi: 10.1080/14647273.2017.1328131. Epub 2017 May 26.